Table 2. Studies with standard and extended rituximab dose in WM, including this study by the Waldenstrom's Macroglobulinemia Clinical Trials Group (WMCTG)
|
N |
Median no. of infusions |
Major RR |
Response duration |
|
| Byrd et al. [7] |
6 |
4 |
57% |
6.6+ months |
| Treon et al. [8] |
30 |
4 |
27% |
8.4 months |
| Weber et al. [9] |
8 |
4 |
75% |
9.0 months |
| Foran et al. [10] |
7 |
4 |
29% |
NA |
| Gertz et al. [11] |
69 |
4 |
27% |
27+ months |
| Dimopoulos et al. [13] |
27 |
8 |
44% |
16+ months |
| WMCTG |
29 |
8 |
48% |
29+ months |
|
Major response rate (RR) reflects percentage of patients achieving partial and complete responses only.
